Please assess the completion status of the following clinical trial:

Trial Title: Pharmacotoxicology of Trichloroethylene Metabolites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy~* normal screening labs~Exclusion Criteria:~* no gastrointestinal surgery~* no smoking~* no medication~* not pregnant

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1A: Chloral Hydrate and DCA: Env (Type: EXPERIMENTAL): Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
- 1B: Chloral Hydrate Env dose (Type: EXPERIMENTAL): Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
- 2A: Chloral Hydrate and DCA therapeutic (Type: EXPERIMENTAL): Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
- 2B: Chloral Hydrate Therapeutic (Type: EXPERIMENTAL): Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)

Based on this trial design, predict the completion outcome and termination type (if applicable).